Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer
This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to
Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is sponsoring
this trial.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response to treatment with ZK-Epo after 6 cycles
After 6 cycles
No
Bayer Study Director
Study Director
Bayer
United States: Food and Drug Administration
91476
NCT00325351
August 2006
March 2009
Name | Location |
---|---|
Albany, Georgia 31701 | |
Phoenix, Arizona 85012 | |
Fountain Valley, California 92708 | |
Cleveland, Ohio 44195 | |
Nashville, Tennessee 37203-1632 | |
McLean, Virginia 22101 | |
Little Rock, Arkansas 72205-7199 | |
Albuquerque, New Mexico 87131-5636 | |
Baltimore, Maryland 21287 | |
Charlotte, North Carolina | |
Indianapolis, Indiana | |
Tulsa, Oklahoma |